A comparison of portal vein embolization with poly(2-hydroxyethylmethacrylate) and a histoacryl/lipiodol mixture in patients scheduled for extended right hepatectomy
Language English Country Czech Republic Media print-electronic
Document type Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
26047385
DOI
10.33549/physiolres.932992
PII: 932992
Knihovny.cz E-resources
- MeSH
- Enbucrilate pharmacology therapeutic use MeSH
- Ethiodized Oil pharmacology therapeutic use MeSH
- Hepatectomy methods MeSH
- Liver drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Polyhydroxyethyl Methacrylate pharmacology therapeutic use MeSH
- Aged MeSH
- Embolization, Therapeutic methods MeSH
- Portal Vein drug effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Enbucrilate MeSH
- Ethiodized Oil MeSH
- Polyhydroxyethyl Methacrylate MeSH
To determine whether PHEMA [poly(2-hydroxyethylmethacrylate)] is suitable for portal vein embolization in patients scheduled to right hepatectomy and whether it is as effective as the currently used agent (a histoacryl/lipiodol mixture). Two groups of nine patients each scheduled for extended right hepatectomy for primary or secondary hepatic tumor, had right portal vein embolization in an effort to induce future liver remnant (FLR) hypertrophy. One group had embolization with PHEMA, the other one with the histoacryl/lipiodol mixture. In all patients, embolization was performed using the right retrograde transhepatic access. Embolization was technically successful in all 18 patients, with no complication related to the embolization agent. Eight patients of either group developed FLR hypertrophy allowing extended right hepatectomy. Likewise, one patient in each group had recanalization of a portal vein branch. Histology showed that both embolization agents reach the periphery of portal vein branches, with PHEMA penetrating somewhat deeper into the periphery. PHEMA has been shown to be an agent suitable for embolization in the portal venous system comparable with existing embolization agent (histoacryl/lipiodol mixture).
References provided by Crossref.org